1110 related articles for article (PubMed ID: 18779710)
21. Intravitreal bevacizumab for diabetic macular edema associated with severe capillary loss: one-year results of a pilot study.
Bonini-Filho M; Costa RA; Calucci D; Jorge R; Melo LA; Scott IU
Am J Ophthalmol; 2009 Jun; 147(6):1022-30, 1030.e1-5. PubMed ID: 19327746
[TBL] [Abstract][Full Text] [Related]
22. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
Retina; 2007; 27(4):432-8. PubMed ID: 17420694
[TBL] [Abstract][Full Text] [Related]
23. Early intravitreal bevacizumab for non-ischaemic central retinal vein occlusion.
Rensch F; Jonas JB; Spandau UH
Acta Ophthalmol; 2009 Feb; 87(1):77-81. PubMed ID: 18937800
[TBL] [Abstract][Full Text] [Related]
24. Repeated intravitreal injection of bevacizumab for clinically significant diabetic macular edema.
Roh MI; Byeon SH; Kwon OW
Retina; 2008 Oct; 28(9):1314-8. PubMed ID: 18728621
[TBL] [Abstract][Full Text] [Related]
25. [Triamcinolone in the treatment of the diabetic macular edema--one-year results].
Dusová J; Studnicka J; Rencová E; Korda V; Hejcmanová D
Cesk Slov Oftalmol; 2008 Jul; 64(4):149-52. PubMed ID: 18780654
[TBL] [Abstract][Full Text] [Related]
26. Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up.
Arevalo JF; Sanchez JG; Fromow-Guerra J; Wu L; Berrocal MH; Farah ME; Cardillo J; Rodríguez FJ;
Graefes Arch Clin Exp Ophthalmol; 2009 Jun; 247(6):735-43. PubMed ID: 19189118
[TBL] [Abstract][Full Text] [Related]
27. Intravitreal bevacizumab (Avastin) for primary treatment of diabetic macular oedema.
Ozkiriş A
Eye (Lond); 2009 Mar; 23(3):616-20. PubMed ID: 18437176
[TBL] [Abstract][Full Text] [Related]
28. A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations.
Algvere PV; Steén B; Seregard S; Kvanta A
Acta Ophthalmol; 2008 Aug; 86(5):482-9. PubMed ID: 18162062
[TBL] [Abstract][Full Text] [Related]
29. Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion.
Rabena MD; Pieramici DJ; Castellarin AA; Nasir MA; Avery RL
Retina; 2007; 27(4):419-25. PubMed ID: 17420692
[TBL] [Abstract][Full Text] [Related]
30. Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion.
Spaide RF; Chang LK; Klancnik JM; Yannuzzi LA; Sorenson J; Slakter JS; Freund KB; Klein R
Am J Ophthalmol; 2009 Feb; 147(2):298-306. PubMed ID: 18929354
[TBL] [Abstract][Full Text] [Related]
31. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration in treatment-naive patients.
Pedersen KB; Sjølie AK; Møller F
Acta Ophthalmol; 2009 Nov; 87(7):714-9. PubMed ID: 19094171
[TBL] [Abstract][Full Text] [Related]
32. Primary intravitreal bevacizumab for the management of pseudophakic cystoid macular edema: pilot study of the Pan-American Collaborative Retina Study Group.
Arevalo JF; Garcia-Amaris RA; Roca JA; Sanchez JG; Wu L; Berrocal MH; Maia M;
J Cataract Refract Surg; 2007 Dec; 33(12):2098-105. PubMed ID: 18053911
[TBL] [Abstract][Full Text] [Related]
33. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration.
Emerson MV; Lauer AK; Flaxel CJ; Wilson DJ; Francis PJ; Stout JT; Emerson GG; Schlesinger TK; Nolte SK; Klein ML
Retina; 2007; 27(4):439-44. PubMed ID: 17420695
[TBL] [Abstract][Full Text] [Related]
34. Short-term safety and efficacy of intravitreal bevacizumab for pseudophakic cystoid macular edema.
Barone A; Russo V; Prascina F; Delle Noci N
Retina; 2009 Jan; 29(1):33-7. PubMed ID: 18854783
[TBL] [Abstract][Full Text] [Related]
35. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA;
Retina; 2008; 28(10):1387-94. PubMed ID: 18827735
[TBL] [Abstract][Full Text] [Related]
36. Early treatment of severe cystoid macular edema in central retinal vein occlusion with posterior sub-tenon triamcinolone acetonide.
Lin JM; Chiu YT; Hung PT; Tsai YY
Retina; 2007 Feb; 27(2):180-9. PubMed ID: 17290200
[TBL] [Abstract][Full Text] [Related]
37. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
Avery RL; Pieramici DJ; Rabena MD; Castellarin AA; Nasir MA; Giust MJ
Ophthalmology; 2006 Mar; 113(3):363-372.e5. PubMed ID: 16458968
[TBL] [Abstract][Full Text] [Related]
38. Optical coherence tomographic pattern may predict visual outcome after intravitreal triamcinolone for diabetic macular edema.
Gibran SK; Khan K; Jungkim S; Cleary PE
Ophthalmology; 2007 May; 114(5):890-4. PubMed ID: 17467527
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of intravitreal bevacizumab in treating postoperative pseudophakic cystoid macular edema.
Spitzer MS; Ziemssen F; Yoeruek E; Petermeier K; Aisenbrey S; Szurman P
J Cataract Refract Surg; 2008 Jan; 34(1):70-5. PubMed ID: 18165084
[TBL] [Abstract][Full Text] [Related]
40. Treatment of branch retinal vein occlusion induced macular edema with bevacizumab.
Abegg M; Tappeiner C; Wolf-Schnurrbusch U; Barthelmes D; Wolf S; Fleischhauer J
BMC Ophthalmol; 2008 Sep; 8():18. PubMed ID: 18823536
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]